SophorabiosideCAS# 2945-88-2 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 2945-88-2 | SDF | Download SDF |
PubChem ID | 11968944 | Appearance | Powder |
Formula | C27H30O14 | M.Wt | 578.52 |
Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 3-[4-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxyphenyl]-5,7-dihydroxychromen-4-one | ||
SMILES | CC1C(C(C(C(O1)OC2C(C(C(OC2OC3=CC=C(C=C3)C4=COC5=CC(=CC(=C5C4=O)O)O)CO)O)O)O)O)O | ||
Standard InChIKey | SNJVNAXLTOIYQN-XQCQZFFBSA-N | ||
Standard InChI | InChI=1S/C27H30O14/c1-10-19(31)22(34)24(36)26(38-10)41-25-23(35)21(33)17(8-28)40-27(25)39-13-4-2-11(3-5-13)14-9-37-16-7-12(29)6-15(30)18(16)20(14)32/h2-7,9-10,17,19,21-31,33-36H,8H2,1H3/t10-,17+,19-,21+,22+,23-,24+,25+,26-,27+/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Sophorabioside is a natural product from Sophora japonica. |
In vivo | Isolation of antiosteoporotic compounds from seeds of Sophora japonica.[Pubmed: 24892557]PLoS One. 2014 Jun 3;9(6):e98559.Chemical investigation of Sophora japonica seeds resulted in the isolation of seven metabolites identified as: genistin (1), sophoricoside (2), Sophorabioside (3), sophoraflavonoloside (4), genistein 7,4'-di-O-β-D-glucopyransoide (5), kaempferol 3-O-α-L-rhamnopyranosyl(1 → 6)β-D-glucopyranosyl(1 → 2)β-D-glucopyranoside (6) and rutin (7).
|
Sophorabioside Dilution Calculator
Sophorabioside Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.7285 mL | 8.6427 mL | 17.2855 mL | 34.571 mL | 43.2137 mL |
5 mM | 0.3457 mL | 1.7285 mL | 3.4571 mL | 6.9142 mL | 8.6427 mL |
10 mM | 0.1729 mL | 0.8643 mL | 1.7285 mL | 3.4571 mL | 4.3214 mL |
50 mM | 0.0346 mL | 0.1729 mL | 0.3457 mL | 0.6914 mL | 0.8643 mL |
100 mM | 0.0173 mL | 0.0864 mL | 0.1729 mL | 0.3457 mL | 0.4321 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Pseudolycorine
Catalog No.:BCN5371
CAS No.:29429-03-6
- 4',7-Di-O-methylnaringenin
Catalog No.:BCN5197
CAS No.:29424-96-2
- 7-Nitroindazole
Catalog No.:BCC6713
CAS No.:2942-42-9
- Cyclen
Catalog No.:BCN8441
CAS No.:294-90-6
- Secoisolariciresinol
Catalog No.:BCN5196
CAS No.:29388-59-8
- Anhydrosecoisolariciresinol
Catalog No.:BCN7521
CAS No.:29388-33-8
- Ro 90-7501
Catalog No.:BCC7351
CAS No.:293762-45-5
- Thevetiaflavone
Catalog No.:BCN4024
CAS No.:29376-68-9
- T0901317
Catalog No.:BCC1178
CAS No.:293754-55-9
- SR3335
Catalog No.:BCC1964
CAS No.:293753-05-6
- H-Phg-OH
Catalog No.:BCC3310
CAS No.:2935-35-5
- Olean-12-ene-3,11-dione
Catalog No.:BCN5195
CAS No.:2935-32-2
- Ticarcillin sodium
Catalog No.:BCC4737
CAS No.:29457-07-6
- L 006235
Catalog No.:BCC2361
CAS No.:294623-49-7
- Ganoderic acid Z
Catalog No.:BCN2440
CAS No.:294674-09-2
- Narciclasine
Catalog No.:BCN4732
CAS No.:29477-83-6
- Cypellocarpin C
Catalog No.:BCN7556
CAS No.:294856-66-9
- Valerosidate
Catalog No.:BCN6750
CAS No.:29505-31-5
- MNI-caged-L-glutamate
Catalog No.:BCC7086
CAS No.:295325-62-1
- Eupatoletin
Catalog No.:BCN3605
CAS No.:29536-44-5
- Olivil
Catalog No.:BCN5198
CAS No.:2955-23-9
- Negletein
Catalog No.:BCN8085
CAS No.:29550-13-8
- (E)-N-Caffeoylputrescine
Catalog No.:BCC8391
CAS No.:29554-26-5
- Sakuranetin
Catalog No.:BCN5199
CAS No.:2957-21-3
Isolation of antiosteoporotic compounds from seeds of Sophora japonica.[Pubmed:24892557]
PLoS One. 2014 Jun 3;9(6):e98559.
Chemical investigation of Sophora japonica seeds resulted in the isolation of seven metabolites identified as: genistin (1), sophoricoside (2), Sophorabioside (3), sophoraflavonoloside (4), genistein 7,4'-di-O-beta-D-glucopyransoide (5), kaempferol 3-O-alpha-L-rhamnopyranosyl(1 --> 6)beta-D-glucopyranosyl(1 --> 2)beta-D-glucopyranoside (6) and rutin (7). Compounds 1, 2 and 5 showed significant estrogenic proliferative effect in MCF-7 cell in sub-cytotoxic concentration range. Compounds 1 and 2 showed minimal cell membrane damaging effect using LDH leakage assay. Accordingly, compound 2 (sophoricoside, (SPH)) was selected for further in-vivo studies as a potential anti-osteoporosis agent. The anti-osteoporotic effect of SPH was assessed in ovarectomized (OVX) rats after oral administration (15 mg/kg and 30 mg/kg) for 45 days compared to estradiol (10 microg/kg) as a positive control. Only in a dose of 30 mg/kg, SPH regained the original mechanical bone hardness compared to normal non-osteoporotic group. However, SPH (15 mg/kg) significantly increased the level of alkaline phosphatase (ALP) to normal level. Treatment with SPH (30 mg/kg) increased the level of ALP to be higher than normal group. SPH (15 mg/kg) did not significantly increase the serum level of osteocalcin (OC) compared to OVX group. On the other hand, treatment with SPH (30 mg/kg) significantly increased the level of OC to 78% higher than normal non-ovarectomized animals group. In addition, SPH (15 mg/kg) decreased the bone resorption marker, acid phosphatase (ACP) to normal level and SPH (30 mg/kg) further diminished the level of serum ACP. Histopathologically, sophoricoside ameliorated the ovarectomy induced osteoporosis in a dose dependent manner. The drug showed thicker bony trabeculae, more osteoid, and more osteoblastic rimming compared to OVX group.